Recently Approved Drugs: Lutetium Lu 177 dotatate for treatment of GEP-NETs
Jul 18, 2018
06:59
forum Ask episode
view_agenda Chapters
auto_awesome Transcript
info_circle Episode notes
Dr. Jonathan Strosberg, section chief of the Neuroendocrine Tumor Division of the Moffitt Cancer Center, discusses the recent FDA approval of Lutetium Lu 177 dotatate for the treatment of somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors (GEP-NETs).
ASCO Education